Comparison of clinicopathological characteristics between T‐cell prolymphocytic leukemia and peripheral T‐cell lymphoma, not otherwise specified

Kawamoto, Keisuke; Miyoshi, Hiroaki; Yanagida, Eriko; Yoshida, Noriaki; Kiyasu, Junichi; Kozai, Yasuji; Morikita, Tatsuma; Kato, Takumi; Suzushima, Hitoshi; Tamura, Shinobu; Muta, Tsuyoshi; Katô, Kôji; Eto, Tetsuya; Seki, Ritsuko; Nagafuji, Koji; Sone, Hirohito; Takizawa, Jun; Seto, Masao; Ohshima, Koichi

doi:10.1111/ejh.12856

Cited by 14 publications

(11 citation statements)

References 29 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The methodological details regarding determination of the EBV-DNA viral load in peripheral blood, 18 Southern blot hybridization, 8 , 20 T-cell receptor gamma gene rearrangement, 21 , 22 in situ hybridization for EBER, 21 histology and immunophenotyping, 9 determination of EBV-infected cell type, 6 , 22 and statistical analysis 23 were based on previous reports, as described in the Online Supplementary Appendix .…”

Section: Methodsmentioning

confidence: 99%

A distinct subtype of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder: adult patients with chronic active Epstein-Barr virus infection-like features

et al. 2017

Self Cite

View full text Add to dashboard Cite

The characteristics of adult patients with chronic active Epstein-Barr virus infection are poorly recognized, hindering early diagnosis and an improved prognosis. We studied 54 patients with adult-onset chronic active Epstein-Barr virus infection diagnosed between 2005 and 2015. Adult onset was defined as an estimated age of onset of 15 years or older. To characterize the clinical features of these adults, we compared them to those of 75 pediatric cases (estimated age of onset <15 years). We compared the prognosis of adult-onset chronic active Epstein-Barr virus infection with that of patients with nasal-type (n=37) and non-nasal-type (n=45) extranodal NK/T-cell lymphoma. The median estimated age of onset of these lymphomas was 39 years (range, 16–86 years). Compared to patients with pediatric-onset disease, those in whom the chronic active Epstein-Barr virus infection developed in adulthood had a significantly decreased incidence of fever (P=0.005), but greater frequency of skin lesions (P<0.001). Moreover, hypersensitivity to mosquito bites and the occurrence of hydroa vacciniforme were less frequent in patients with adult-onset disease (P<0.001 and P=0.0238, respectively). Thrombocytopenia, high Epstein-Barr virus nuclear antigen antibody titer, and the presence of hemophagocytic syndrome were associated with a poor prognosis (P=0.0087, P=0.0236, and P=0.0149, respectively). Allogeneic hematopoietic stem cell transplantation may improve survival (P=0.0289). Compared to pediatric-onset chronic active Epstein-Barr virus infection and extranodal NK/T-cell lymphoma, adult-onset chronic active Epstein-Barr virus infection had a poorer prognosis (P<0.001 and P=0.0484, respectively). Chronic active Epstein-Barr virus infection can develop in a wide age range, with clinical differences between adult-onset and pediatric-onset disease. Adult-onset chronic active Epstein-Barr virus infection is a disease with a poor prognosis. Further research will be needed.

show abstract

Section: Methodsmentioning

confidence: 99%

A distinct subtype of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder: adult patients with chronic active Epstein-Barr virus infection-like features

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Sections from formalin‐fixed, paraffin‐embedded blocks were stained with hematoxylin‐eosin and analyzed with immunohistochemistry (IHC). At the initial diagnosis, the raw specimens were used for flow cytometry (FCM) to investigate the immunophenotype according to the institutional procedures . The primary antibodies used for IHC and FCM are shown in Table S1.…”

Section: Methodsmentioning

confidence: 99%

“…Epstein‐Barr virus was detected by in situ hybridization with a fluorescein‐conjugated EBV peptide nucleic acid probe kit (Dako Cytomation, Glostrup, Denmark), according to institutional procedures …”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Frequent expression of CD30 in extranodal NK/T‐cell lymphoma: Potential therapeutic target for anti‐CD30 antibody‐based therapy

Kawamoto

Miyoshi

Suzuki

et al. 2017

Hematological Oncology

Self Cite

View full text Add to dashboard Cite

Extranodal NK/T-cell lymphoma, nasal type (ENKTL) is a subtype of non-Hodgkin lymphoma with a poor prognosis. Although first-line treatments for patients with localized ENKTL have been established, there is no gold standard treatment for patients with advanced ENKTL and refractory and/or relapsed disease. Anti-CD30 antibody-based therapy, including brentuximab vedotin (BV), has been shown to target malignant lymphomas with CD30 expression. In particular, this therapeutic agent has recently been suggested to be effective for Hodgkin lymphoma and mature T-cell lymphoma. However, the efficacy of BV toward ENKTL has not yet been established. Therefore, we investigated the expression of CD30 in a large cohort to evaluate BV as a potential treatment for ENKTL. In this study, 97 Japanese patients with newly diagnosed ENKTL between January 2007 and December 2015 were enrolled. Flow cytometry and immunohistochemistry were performed for the evaluation of CD30 expression. If the cut-off value of CD30 expression is 1% or more, there were 55 positive cases (56.5%). According to the localization of lesion, the frequency of CD30 expression was significantly higher in the non-nasal type than in the nasal type (P = .0394). No differences were observed in almost all clinical characteristics between CD30-positive cases and CD30-negative cases. In addition, the expression of CD30 was not a prognostic factor for either overall survival or progression-free survival. In conclusion, frequent expression of CD30 in ENKTL suggests anti-CD30 antibody-based therapy may be an effective treatment.

show abstract

“…When our patient progressed to the leukemic phase, most of peripheral leukocytes were neoplastic cells, which is a rare presentation. The leukemic phase of PTCL indicates poor prognosis [ 3 , 4 ], revealing that lymphoma cells refractory to various chemotherapies survived and could have transformed into more aggressive lymphoma cells.…”

Section: To the Editormentioning

confidence: 99%

Successful response with romidepsin in relapsed peripheral T-cell lymphoma, not otherwise specified with leukemic progression

Sato

Tamai

2020

Blood Res

View full text Add to dashboard Cite

Fig. 1. Computed tomography (CT) findings at relapse showing splenomegaly (A). CT after 2 courses of romidepsin showing that the splenomegaly improved (B). Peripheral blood smear with May-Giemsa staining (C) and histopathological findings from bone marrow biopsy showing diffuse proliferation of medium-sized lymphoid cells (hematoxylin-eosin staining, ×20) (D), indicating a leukemic-phase peripheral T-cell lymphoma. Immunohistochemical staining expressed (E) CD3, (F) CD4 (weakly), and (G) CD8 lymphocytes.

show abstract

Comparison of clinicopathological characteristics between T‐cell prolymphocytic leukemia and peripheral T‐cell lymphoma, not otherwise specified

Abstract: T-PLL and PTCL-NOS may share common biological and clinical characteristics in Japanese patients.

Cited by 14 publications

References 29 publications

A distinct subtype of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder: adult patients with chronic active Epstein-Barr virus infection-like features

A distinct subtype of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder: adult patients with chronic active Epstein-Barr virus infection-like features

Frequent expression of CD30 in extranodal NK/T‐cell lymphoma: Potential therapeutic target for anti‐CD30 antibody‐based therapy

Successful response with romidepsin in relapsed peripheral T-cell lymphoma, not otherwise specified with leukemic progression

Contact Info

Product

Resources

About